Protagonist Therapeutics, Inc. PTGX

The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics), PN-881 (Protagonist Therapeutics), and others is expected to significantly reshape the Psoriatic Arthritis (PsA) market by expanding treatment options and addressing unmet needs among patients with inade

NEWARK, CA / ACCESS Newswire / September 8, 2026 / , Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.

On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the […]

U.S. Food and Drug Administration approval of MIMRYLO, or rusfertide, for erythrocytosis in adults with polycythemia vera triggered $275 million in payments to Protagonist Therapeutics, Inc. (NASDAQ:PTGX). The amount consists of an additional $200 million opt-out fee and a separate $75 million approval milestone. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) chose royalties over the original 50:50 U.S. […]

NEWARK, CA / ACCESS Newswire / September 2, 2026 / (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V., President and Chief Executive Officer, will participate in two investment bank conferences taking place in September 2026.

Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, investors are weighing how much of the good news is already reflected in the price. Over the past 3 years, Protagonist Therapeutics has gained roughly 6.5 times its earlier level. This puts extra focus on whether recent enthusiasm has pushed the valuation...

Protagonist Therapeutics recently reported that the U.S. FDA approved MIMRYLO (rusfertide), the first hepcidin mimetic peptide therapy for adults with polycythemia vera, a rare blood cancer. This regulatory milestone also activates milestone payments from partner Takeda, underlining how MIMRYLO’s unique mechanism could reshape treatment options in this indication. We’ll now examine how FDA approval of MIMRYLO and the associated Takeda milestone payments influence Protagonist Therapeutics’...

Why Protagonist Therapeutics Is Back In Focus After Investor Update Call Protagonist Therapeutics (PTGX) has drawn fresh attention after hosting a special call on 29 August 2026 to discuss its latest investor update, prompting many shareholders to reassess the stock. The special call comes after a strong run in Protagonist Therapeutics, with the latest share price at $147.75 and a 90 day share price return of 58.48%, along with a very large 3 year total shareholder return. However, the 7 day...

Protagonist Therapeutics (NasdaqGM: PTGX) reported U.S. FDA approval of MIMRYLO (rusfertide) as a first in class hepcidin mimetic peptide for adults with polycythemia vera. The approval makes MIMRYLO the only FDA approved hepcidin mimetic therapy available for this rare blood cancer. The decision triggers milestone payments from partner Takeda to Protagonist Therapeutics, linked to clinical and commercial progress for MIMRYLO. This approval highlights how drug developers using advanced...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.

MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully Reduce Phlebotomy Burden, and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Response During Weeks 20-32FDA Approval Triggers $275M in Milestones, 14%-29% Royalties, with Up to an Additional $875M in Potential Future MilestonesInvestor c

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer ...